CAS: 67-16-3; N,N'-(Disulfanediylbis(5-Hydroxypent-2-Ene-3,2-Diyl))Bis(N-((4-Amino-2-Methylpyrimidin-5-yl)Methyl)Formamide)

上下游产品

CAS号100502-53-2 N,N'-(disulfane... | CAS号100502-55-4 N,N'-(disulfane... | CAS号490-82-4 硫代硫胺素

N,N'-(Disulfanediylbis(5-Hydroxypent-2-Ene-3,2-Diyl))Bis(N-((4-Amino-2-Methylpyrimidin-5-yl)Methyl)Formamide) Heptadecanoate 以 水作为反应溶剂,获得 十七烷酸,Thiamine Disulfide
参考文献:Kinetic Study On The Release Of Thiamine Disulfide(Tds) From Tds-Higher Fatty Acids Complexes.
标题:Kinetic Study On The Release Of Thiamine Disulfide(Tds) From Tds-Higher Fatty Acids Complexes.
摘要:测定了在不同温度下奇数脂肪酸-Tds 复合物(C2N-1)6(Tds)中二硫化硫胺(Tds)的释放速率,并估算了复合物中tds释放动力学中的热力学量.络合物释放 Tds 的活化吉布斯能δg〓和活化焓δh〓均为正值.将(C2N-1)6 (Tds)的结果与之前偶数脂肪酸-Tds 复合物(C2N)6(Tds)的结果进行了比较.从络合物中释放 Tds 的速率常数与组成脂肪酸的碳数之间的关系图显示出一种之字形模式,表明在奇数位置向下凸.此外,δh〓的正值与组成脂肪酸的碳数的关系图显示出一条之字形线,表示在奇数位置向上凸,而δs〓的负值与组成脂肪酸的碳数的关系图显示出一条之字形线,表示在奇数位置向下凸.与(C2N)6(Tds)相比,(C<2N-1>)6(Tds)释放 Tds 从活化焓角度看更不利,从活化熵角度看更有利.研究发现,(C2N-1)6(Tds) 中 Tds 的释放是一个焓控制反应,由于焓效应,释放更为不利.过渡中间体的热力学参数可以解释 Tds 从配合物中释放速率的 "之 "字形线.
Doi:10.1248/Cpb.38.1819

专利信息

专利号:US-4272507-A
优先权日:1978-05-24
标 题:Phenylaminothiophenacetic acids, their synthesis, compositions and use
发明人：FIGALA VOLKER
权利人:BYK GULDEN LOMBERG CHEM FAB
摘要:Phenylaminothiophenacetic acids of formula I (I) wherein R1 denotes a hydrogen atom, a chlorine atom, a bromine atom or a methyl group, R2 denotes a -CH2-COOH group or a -CH2-COOR6 group, R3 denotes a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or a trifluoromethyl group, R4 has one of the meanings of R3, R5 denotes a hydrogen atom, a halogen atom or an alkyl group, R6 denotes an alkyl group (with from 1 to 5 carbon atoms), which is optionally substituted by hydroxyl, hydroxyalkoxy or alkanoyloxy groups, or a benzyl group and n denotes 1 or 2, and salts of the acids have outstanding antiphlogistic, analgesic and antipyretic activities.

专利号:US-8440810-B2
优先权日:2002-09-20
标 题:Riboswitches, methods for their use, and compositions for use with riboswitches
发明人：BREAKER RONALD R; NAHVI ALI; SUDARSAN NARASIMHAN; EBERT MARGARET S; WINKLER WADE; BARRICK JEFFREY E; WICKISER JOHN K
权利人:BREAKER RONALD R; NAHVI ALI; SUDARSAN NARASIMHAN; EBERT MARGARET S; WINKLER WADE; BARRICK JEFFREY E; WICKISER JOHN K; UNIV YALE
摘要:It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitchesâ€? (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen—turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapytreatments.